Rivaroxaban for the treatment of cerebral venous thrombosis

BACKGROUND: New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebra...

Descripción completa

Detalles Bibliográficos
Autores principales: Esmaeili, Sara, Abolmaali, Meysam, Aarabi, Sobhan, Motamed, Mohammad Reza, Chaibakhsh, Samira, Joghataei, Mohammad Taghi, Mojtahed, Mohammad, Mirzaasgari, Zahra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883416/
https://www.ncbi.nlm.nih.gov/pubmed/33588777
http://dx.doi.org/10.1186/s12883-021-02091-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883416/
https://www.ncbi.nlm.nih.gov/pubmed/33588777
http://dx.doi.org/10.1186/s12883-021-02091-1

Ejemplares similares